A process for the purification of L--glycerophosphorylcholine is described, wherein L--glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L--glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L--glycerophosphorylcholine is also described, comprising the elution of L--glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L--glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.

An object t of the present invention is to proroaide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1): ##STR00001##

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

An object t of the present invention is to provide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):

##STR00001##

An object of the present invention is to provide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):

##STR00001##

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

An electrolyte including: a lithium salt, a non-aqueous solvent, an alkyl sulfonate compound represented by Formula 2, and an unsaturated sulfone compound represented by Formula 3:

##STR00001## wherein, in Formula 2, Q.sub.1 and Q.sub.2 are each independently a substituted or unsubstituted C.sub.1-C.sub.20 alkyl group, and in Formula 3, Q.sub.3 and Q.sub.4 are each independently a group represented by -(L.sub.1)-(R.sub.1), a vinyl group, an allyl group, or a substituted or unsubstituted C.sub.1-C.sub.20 alkyl group, and at least one of Q.sub.3 or Q.sub.4 is a group represented by -(L.sub.1)-(R.sub.1), a vinyl group, or an allyl group, Li is a substituted or unsubstituted C.sub.2-C.sub.20 alkenylene group or a substituted or unsubstituted C.sub.2-C.sub.20 alkynylene group, and Ri is hydrogen or a substituted or unsubstituted C.sub.2-C.sub.20 alkyl group.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

A process is provided for preparing a salt of a hydroxy-substituted di-ester of phosphoric acid, comprising: (a) reacting a phosphating agent with a monohydric alcohol and with a propylene glycol, wherein the mole ratio of monohydric alcohol : propylene glycol is greater than about 4:1 and wherein an excess of the phosphating agent is employed such that the product mixture formed thereby contains phosphorus acid functionality; and (b) reacting the product mixture of step (a) with an amine. The product is useful as an antiwear agent.

There are described ROR modulators of the formula (I), ##STR00001##
and formula (II) ##STR00002##
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR activity, for example, autoimmune and/or inflammatory disorders.